Roche To Reinvest Savings Into R&D And Keep Prices Low
R&D Productivity Gains Are Key
The Swiss major's pharma chief Bill Anderson tells Scrip that the goal for the firm over the next decade is to deliver twice as many medicines at a much lower cost to society.
